# A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

> **NCT04996121** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** XZP-5955 tablets

## Key facts

- **NCT ID:** NCT04996121
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-06
- **Primary completion:** 2025-09
- **Final completion:** 2027-06
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2022-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996121, "A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04996121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*